Bacteremia, Infection, Bacterial
Conditions
Brief summary
This study aims to assess whether ertapenem as an empiric treatment of third-generation-cephalosporin resistant Enterobacteriaceae (3GCRE) bacteremia is non-inferior to other carbapenems in term of 30-day mortality.
Detailed description
There are limited data of the efficacy of ertapenem as the empiric treatment of serious invasive infections, such as bloodstream infections (BSIs), that are due to ESBL-producing Enterobacteriaceae. Previous studies of ertapenem were done in small group of patients, in less invasive infection, as a definite 'step-down' therapy, or as compared to other non-carbapenem antibiotics.
Interventions
DRUGErtapenem
Ertapenem injection
DRUGCarbapenems
Other carbapenems injection
Sponsors
Phramongkutklao College of Medicine and Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
* Adults, either sex, ages 18 years or above * Patients with 3GCRE bacteremia * Patients admitted to any of the study sites
Exclusion criteria
* Discontinuation of antibiotic due to transition to hospice care * Polymicrobial bacteremia * Empirical antibiotic after 24 hours of first evidence of bacteremia
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 30-day mortality | 30 days | death from any cause within 30 days after the blood culture with bacteraemia is drawn |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| In-hospital mortality | 90 days | death from any cause within the duration of admission with bacteraemia |
| 14-day mortality | 14 days | death from any cause within 14 days after the blood culture with bacteraemia is drawn |
| 90-day mortality | 90 days | death from any cause within 90 days after the blood culture with bacteraemia is drawn |
| • Length of stay | 90 days | Duration of admission with bacteraemia |
Countries
Thailand
Outcome results
None listed